Takeda collaborates with Cardiff University psychiatric disorders research

Japanese pharma major Takeda Pharmaceutical (TYO: 4502) has formed a drug discovery collaboration with Wales-based Cardiff University to identify new approaches for treating schizophrenia and other psychiatric disorders.

The collaboration will combine the University’s large scale genomic data, and world-class expertise in psychiatric genetics, genomics and neuroscience, with Takeda’s extensive drug discovery and clinical development capabilities.

“Recent developments in psychiatric genetics and genomics, combined with advances in neuroscience, mean there is now a real prospect of overcoming the obstacles that have held back progress in developing new drugs for psychiatric disorders,” said Professor Lawrence Wilkinson, scientific director of the Neuroscience and Mental Health Research Institute (NMHRI) who will co-lead the partnership at Cardiff.